title: Hope, quality of life, and benefit from treatment in women having chemotherapy for platinum-resistant/refractory recurrent ovarian cancer: the gynecologic cancer intergroup symptom benefit study.
abstract: Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. We sought to determine the relationships between: (a) trait hope, expectation of symptom benefit from chemotherapy, and anxiety and depression; (b) hope and perceived efficacy of chemotherapy; and (c) unfulfilled hope (where expectations for benefit are not fulfilled) and depression. Methods. Adult patients enrolled within stage 1 of the Gynecologic Cancer Intergroup Symptom Benefit Study were included. Patient. Reported outcomes were collected from 126 women with predominantly platinum-resistant ovarian cancer at baseline, prior to the first four treatment cycles (12-16 weeks), and four weeks after completing chemotherapy or at disease progression, whichever came first. Associations were assessed with Spearman rank correlation coefficient (r) and odds ratio. Results. Trait hope and expectation of symptom benefit from chemotherapy were weakly correlated with each other (r = 0.25). Trait hope, but not expectation of symptom benefit, was negatively correlated with anxiety (r = -0.43) and depression (r = -0.50). The smaller the discrepancy between perceived and expected symptom benefit, the less likely the patient was to have scores indicative of depression (odds ratio: 0.68; 95% confidence interval: 0.49-0.96; p = .026). Conclusion. Trait hope and expectation of symptom benefit from chemotherapy appear to be distinct and independent of the aspects of quality of life and scores for depression. Hope did not appear to affect perceived efficacy of chemotherapy in alleviating symptoms, but women whose expectation of symptom benefit from chemotherapy was not fulfilled were more likely to have scores indicative of depression. It may be preferable to encourage hope toward achievable goals rather than toward benefits from chemotherapy.
authors.affiliation: Australian and New Zealand Gynaecological Oncology Group and National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia;
authors.forename: Katrin M
authors.initials: KM
authors.lastname: Sjoquist
authors.forename: Michael L
authors.initials: ML
authors.lastname: Friedlander
authors.forename: Rachel L
authors.initials: RL
authors.lastname: O'Connell
authors.forename: Merryn
authors.initials: M
authors.lastname: Voysey
authors.forename: Madeleine T
authors.initials: MT
authors.lastname: King
authors.forename: Martin R
authors.initials: MR
authors.lastname: Stockler
authors.forename: Amit M
authors.initials: AM
authors.lastname: Oza
authors.forename: Kim
authors.initials: K
authors.lastname: Gillies
authors.forename: Julie K
authors.initials: JK
authors.lastname: Martyn
authors.forename: Phyllis N
authors.initials: PN
authors.lastname: Butow
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001007:Anxiety / Q000209:etiology / Q000523:psychology; D000077216:Carcinoma, Ovarian Epithelial; D003863:Depression / Q000209:etiology / Q000523:psychology; D019008:Drug Resistance, Neoplasm; D005260:Female; D065026:Hope; D006801:Humans; D008137:Longitudinal Studies; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000523:psychology; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000523:psychology*; D009944:Organoplatinum Compounds / Q000494:pharmacology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D011379:Prognosis; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds
keywords: Chemotherapy; Hope; Recurrent ovarian cancer; Symptom benefit; Symptoms